AU758566B2 - Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor - Google Patents

Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor Download PDF

Info

Publication number
AU758566B2
AU758566B2 AU11926/99A AU1192699A AU758566B2 AU 758566 B2 AU758566 B2 AU 758566B2 AU 11926/99 A AU11926/99 A AU 11926/99A AU 1192699 A AU1192699 A AU 1192699A AU 758566 B2 AU758566 B2 AU 758566B2
Authority
AU
Australia
Prior art keywords
alkyl
benzenesulfonamide
radicals
pyrazol
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU11926/99A
Other languages
English (en)
Other versions
AU1192699A (en
Inventor
Jaime Masferrer
Philip Needleman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of AU1192699A publication Critical patent/AU1192699A/en
Application granted granted Critical
Publication of AU758566B2 publication Critical patent/AU758566B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU11926/99A 1997-10-31 1998-10-27 Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor Ceased AU758566B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6388997P 1997-10-31 1997-10-31
US60/063889 1997-10-31
PCT/US1998/022246 WO1999022720A2 (en) 1997-10-31 1998-10-27 Selective cyclooxygenase-2 inhibitors against premature labor

Publications (2)

Publication Number Publication Date
AU1192699A AU1192699A (en) 1999-05-24
AU758566B2 true AU758566B2 (en) 2003-03-27

Family

ID=22052179

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11926/99A Ceased AU758566B2 (en) 1997-10-31 1998-10-27 Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor

Country Status (9)

Country Link
EP (1) EP1027048A2 (US06815460-20041109-C00023.png)
JP (1) JP2001521889A (US06815460-20041109-C00023.png)
AR (1) AR014000A1 (US06815460-20041109-C00023.png)
AU (1) AU758566B2 (US06815460-20041109-C00023.png)
BR (1) BR9813164A (US06815460-20041109-C00023.png)
CA (1) CA2308639A1 (US06815460-20041109-C00023.png)
TW (2) TW577739B (US06815460-20041109-C00023.png)
WO (1) WO1999022720A2 (US06815460-20041109-C00023.png)
ZA (1) ZA989876B (US06815460-20041109-C00023.png)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1353664A2 (en) * 2000-06-08 2003-10-22 The Board Of Regents, The University Of Texas System Heterocycle derivatives and methods of use for treating anthrax infection
PL1534305T3 (pl) 2003-05-07 2007-03-30 Osteologix As Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026731A1 (en) * 1993-05-13 1994-11-24 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
WO1995000501A2 (en) * 1993-06-24 1995-01-05 Merck Frosst Canada Inc. Phenyl heterocycles as cyclooxygenase-2 inhibitors
WO1997031631A1 (en) * 1996-02-27 1997-09-04 Rpms Technology Limited Cox-2 selective inhibitors for managing labour and uterine contractions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026731A1 (en) * 1993-05-13 1994-11-24 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
WO1995000501A2 (en) * 1993-06-24 1995-01-05 Merck Frosst Canada Inc. Phenyl heterocycles as cyclooxygenase-2 inhibitors
WO1997031631A1 (en) * 1996-02-27 1997-09-04 Rpms Technology Limited Cox-2 selective inhibitors for managing labour and uterine contractions

Also Published As

Publication number Publication date
JP2001521889A (ja) 2001-11-13
AU1192699A (en) 1999-05-24
AR014000A1 (es) 2001-01-31
EP1027048A2 (en) 2000-08-16
TW200404535A (en) 2004-04-01
TW577739B (en) 2004-03-01
CA2308639A1 (en) 1999-05-14
WO1999022720A2 (en) 1999-05-14
BR9813164A (pt) 2000-08-22
WO1999022720A3 (en) 1999-08-26
ZA989876B (en) 1999-10-29

Similar Documents

Publication Publication Date Title
US6342510B1 (en) Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
US5990148A (en) Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
AU745797B2 (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
EP0880362B1 (en) Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b 4 receptor antagonist
US6136839A (en) Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
EP0888127B1 (en) Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
US6407140B1 (en) Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US20020035156A1 (en) Combination therapy in the prevention of cardiovascular disorders
US20070072861A1 (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
AU758566B2 (en) Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor
EP1400242A1 (en) Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor
US20030008870A1 (en) Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dysmenorrhea
MXPA99009495A (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)